External Validity of Clinical Trials in Acute Myocardial Infarction
Open Access
- 8 January 2007
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 167 (1), 68-73
- https://doi.org/10.1001/archinte.167.1.68
Abstract
Randomized clinical trials (RCTs) provide the foundation for evidence-based medicine. The treatment of patients with acute myocardial infarction (AMI) has advanced dramatically through a series of large international RCTs evaluating the benefits and risks of new therapeutic strategies, and these advances have led to the codification of treatment through practice guidelines.1,2 The relevance of RCTs to clinical practice may be hampered by doubts regarding their external validity,3 particularly because they tend to recruit highly selected populations that may not be representative of patients encountered in everyday practice.4Keywords
This publication has 3 references indexed in Scilit:
- Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarctionThe Lancet, 2001
- Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromesAmerican Heart Journal, 2001
- EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1986